AZ-PROTEOR
11.12.2020 18:02:10 CET | Business Wire | Press release
Proteor, a France-based international group specialized in prosthetic and orthotic solutions, has successfully completed its acquisition of American brand Freedom Innovations and the major part of the product portfolio from Ottobock. With this acquisition, the Proteor group is fueling its strategy to be a global leader in the international orthopaedic market. Proteor’s growth is accelerating with the addition of Freedom Innovation’s quality production, high-tech development, and well-known products: the microprocessor-controlled knee Plie3, the Kinnex and Kinterra ankles and the Agilix, DynAdapt, Sierra, Highlander and Pacifica carbon feet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201211005432/en/
“I would like to thank all Freedom Innovations for their continued dedication, focus, hard work, and professionalism during this unpredictable time. We look forward to coming together as one family.” says Edouard Archambeaud, member of the Board of Directors of Proteor. “I would also like to thank Ottobock for working diligently towards a successful outcome and the FTC for their vote of confidence in our acquisition.”
The united organization counts more than 1,000 employees worldwide, more than doubling the US team, bolstered by four global innovation centers and a full product pipeline. The unique microprocessor products and added lower extremity prosthetics differentiate and expand the Proteor portfolio. The sales and support network is also strengthened, increasing contact with clinical customers.
“For all parties involved and especially for the employees of Freedom Innovations, the final solution is good news after several years of uncertainty and sets the future for Freedom Innovations under the roof of both Proteor and Ottobock”, says Philipp Schulte-Noelle, CEO of Ottobock. “I am especially grateful for the very constructive dialogue with the FTC in recent months and the engagement of Proteor.”
Proteor welcomes more than 100 members of the Freedom Innovations team in manufacturing, sales, marketing, R&D and clinical studies from Gunnison (Utah), Irvine (California) and Germany.
“I am thrilled with the energy and momentum this change brings,” said Matt Swiggum, President and CEO of Proteor USA. “It positions us for continued growth, building on our commitment to innovation and investment in our customers and their patients.”
Proteor’s journey centers on its customers. To uphold its focus on customer relationships and service, Proteor is working closely with Ottobock to facilitate a smooth and seamless transition of the Freedom Innovations business acquired by Proteor. Ottobock retains a substantial part of the prosthetic feet business with Kintrol foot-ankle prosthesis, the Maverick product family and other carbon feet.
We are Proteor
#HumanFirst
About Proteor:
Proteor, an independent family-company, was established more than 100 years ago headquartered in Dijon (France). Proteor operates within the O&P industry with three strategic pillars: software’s, components and custom-made devices. Thanks to continuous investments in innovation, many medical and scientific partnerships, and day to day cooperation with CPOs, Proteor enjoys a recognized expertise all over the O&P community.
For additional information visit: http://www.proteorusa.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201211005432/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Techtronic Industries Delivers Strong First Half Performance4.8.2026 13:20:00 CEST | Press release
Growing Sales to US$8.3 Billion, Net Profit Increased to US$738 Million Techtronic Industries Co. Ltd. (“TTI” or the “Group”) (stock code: HK: 0669, ADR symbol: TTNDY), a global cordless power tool, outdoor power equipment and floorcare & cleaning company, is pleased to announce its results for the six-month period ended June 30, 2026. The Group delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion. Its two leading brands, MILWAUKEE and RYOBI, both delivered a strong performance in the first half of 2026, growing at a combined 8.2% underlying growth rate in local currency. TTI delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion and net profit increasing 17.5% to US$738 million. Our global MILWAUKEE business grew 10.5% on an underlying basis in local currency, after adjusting for the planned 2025 timing impact related to the MILWAUKEE Americas ERP system conversion. RYOBI, the #1 global consumer cordless tool and ou
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom